Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Annovis Bio, Inc. Common Stock (NY: ANVS )

2.730 +0.130 (+5.00%)
Official Closing Price Updated: 7:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Annovis Bio, Inc. Common Stock

< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Better Biotech Stock: Biogen vs. Annovis Bio
Both are making Alzheimer's drugs, but only one can claim success as of today. 
Via The Motley Fool
58 Biggest Movers From Yesterday
Gainers MediaCo Holding Inc. (NASDAQ: MDIA) shares jumped 311.6% to close at $17.00 on Monday after jumping 20% on Friday. State Auto Financial Corporation (NASDAQ: STFC) shares... 
Via Benzinga
38 Stocks Moving In Monday's Mid-Day Session
Gainers State Auto Financial Corporation (NASDAQ: STFC) shares jumped 189.5% to $49.96 after the company agreed to be acquired by Liberty Mutual Insurance for $52 per share in... 
Via Benzinga
Neurodegenerative Disease And Cancer Stocks Among Top Biotech Gainers In 2021
Biotech stocks underperformed the broader market in the first half of 2021, with the iShares Nasdaq Biotechnology ETF IBB advancing about 8% year-to-date compared to the roughly 14% gain for the S&P... 
Via Talk Markets
Topics Stocks
Exposures US Equities
Neurodegenerative Disease, Cancer Stocks Among Top Biotech Gainers In 2021
Biotech stocks underperformed the broader market in the first half of 2021, with the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB) advancing about 8% year-to-date ... 
Via Benzinga
Annovis Bio to Present Data at Alzheimer's Association International Conference 2021 Highlighting Positive Clinical Outcomes from Its Two Phase 2a Trials
Berwyn, Pennsylvania--(Newsfile Corp. - July 2, 2021) - Annovis Bio, Inc. (NYSE American: ANVS), ("Annovis" or the "Company"), a clinical-stage... 
Via Newsfile
Annovis Bio CEO Wins 2021 PACT Enterprise Award for Life Sciences and Healthcare CEO
Berwyn, Pennsylvania--(Newsfile Corp. - July 1, 2021) - Annovis Bio, Inc. (NYSE American: ANVS), ("Annovis" or the "Company"), a clinical-stage... 
Via Newsfile
Annovis Bio CEO Selected as a Finalist in the 2021 PACT Enterprise Awards
Berwyn, Pennsylvania--(Newsfile Corp. - June 24, 2021) - Annovis Bio, Inc. (NYSE American: ANVS), ("Annovis" or the "Company"), a clinical-stage... 
Via Newsfile
44 Biggest Movers From Yesterday
Gainers Alfi, Inc. (NASDAQ: ALF) shares jumped 108.9% to settle at $16.29 on Tuesday following exclusive Benzinga reporting the company will buyback up to $2 million of its... 
Via Benzinga
Stocks That Hit 52-Week Highs On Thursday
This morning 94 companies set new 52-week highs. Things to Consider: NVIDIA (NASDAQ:NVDA) was the largest firm by market cap to set a new 52-week high. Deswell Industries... 
Via Benzinga
These 2 Biotech Stocks Are Up 1,000% This Year
New approaches to treating Alzheimer's could mean even bigger gains in the future. 
Via The Motley Fool
64 Biggest Movers From Friday
Gainers Kanzhun Limited (NASDAQ: BZ) shares climbed 95.8% to close at $37.20 on Friday after the company priced its IPO at $19 per share. Novan, Inc. (NASDAQ: NOVN) shares gained... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Biotechs Ready To Roar
The biggest event last week was the FDA decision to approve Biogen's drug aducanumab, a treatment for Alzheimer's disease. The decision will reverberate across the industry and the healthcare sector... 
Via Talk Markets
Exposures Product Safety
46 Stocks Moving In Friday's Mid-Day Session
Gainers Kanzhun Limited (NASDAQ: BZ) shares surged 77.4% to $33.70 after the company priced its IPO at $19 per share. Novan, Inc. (NASDAQ: NOVN) shares jumped 73.3% to $15.67... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Ignore Biogen: 3 Reasons These Stocks Will Be Better Alzheimer's Investments
Data doesn't lie. These companies have the potential to quickly steal the spotlight. 
Via The Motley Fool
Exposures Product Safety
Annovis Bio to Present at 2021 BIO Digital
Berwyn, Pennsylvania--(Newsfile Corp. - June 10, 2021) - Annovis Bio, Inc. (NYSE American: ANVS), ("Annovis" or the "Company"), a clinical-stage... 
Via Newsfile
This Biotech Stock Is Up 884% In 2021, But It Could Go Even Higher
With updates from clinical trials expected as soon as this month, anything is possible. 
Via The Motley Fool
Biogen Snagged: Will Hefty Price Tag Hinder Alzheimer's Drug Use?
Biogen stock dipped Tuesday as analysts questioned how much use its potential blockbuster Alzheimer's treatment, Aduhelm, would ultimately secure. 
Via Investor's Business Daily
Annovis' Alzheimer's/Parkinson's Candidate Protects Nerve Cells Against Ill Effects of Higher Neurotoxic Proteins
Annovis Bio Inc (NYSE: ANVS) has announced preliminary data demonstrating that ANVS401 protects certain nerve cells from dying after being infected by gingipains, which... 
Via Benzinga
Annovis Bio Expands Potential Application of ANVS401 to Infectious Diseases with New Preclinical Study
Berwyn, Pennsylvania--(Newsfile Corp. - June 8, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a... 
Via Newsfile
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Forget Biogen: These 2 Alzheimer's Drug Stocks Could Make You Rich
There are better options for investors looking to profit from potential Alzheimer's disease treatments. 
Via The Motley Fool
Exposures Product Safety
Biogen Wins Landmark Alzheimer's Approval: 5 Things To Know About Aducanumab
The FDA approved Biogen's Alzheimer's treatment, aducanumab, on Monday — though Biogen stock remained halted into the long-awaited decision. 
Via Investor's Business Daily
Exposures Product Safety
Annovis Bio to Present at Jefferies Virtual Healthcare Conference 2021
Berwyn, Pennsylvania--(Newsfile Corp. - June 3, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage... 
Via Newsfile
Annovis Bio's ANVS401 Improves Speed and Accuracy in Alzheimer's and in Parkinson's Patients
Berwyn, Pennsylvania--(Newsfile Corp. - June 1, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's... 
Via Newsfile
68 Biggest Movers From Yesterday
Gainers Orbital Energy Group, Inc. (NASDAQ: OEG) shares surged 115.2% to close at $7.64 on Tuesday after the company announced its subsidiary, Gibson Technical Services, reached... 
Via Benzinga
Annovis Bio Engages Global Executive Search Leader Spencer Stuart to Expand its Board and Management Team
Berwyn, Pennsylvania--(Newsfile Corp. - May 28, 2021) - Annovis Bio, Inc. (NYSE American: ANVS), ("Annovis" or the "Company"), a clinical-stage... 
Via Newsfile
Exposures Product Safety
Annovis Bio, Inc. Announces Closing of $50 Million Public Offering
Berwyn, Pennsylvania--(Newsfile Corp. - May 27, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage... 
Via Newsfile
Topics Regulatory Compliance
Exposures Legal Product Safety Regulatory
54 Biggest Movers From Yesterday
Gainers Flanigan's Enterprises, Inc. (NYSE: BDL) shares surged 40.6% to close at $34.90 on Tuesday after the company reported results for the 13 weeks and the 26 weeks ended... 
Via Benzinga
22 Stocks Moving in Monday's Pre-Market Session
Gainers Virgin Galactic Holdings, Inc. (NYSE: SPCE) rose 29.3% to $27.25 in pre-market trading. Virgin Galactic’s VSS Unity spacecraft completed its first spaceflight from... 
Via Benzinga
A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street; Crude Oil Rises
Pre-open movers U.S. stock futures traded higher in early pre-market trade after the Dow Jones surged over 100 points in the previous session. Investors are awaiting earnings... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.